{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:45:54Z","timestamp":1782380754188,"version":"3.54.5"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20106"],"award-info":[{"award-number":["U23A20106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3403300"],"award-info":[{"award-number":["2023YFC3403300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lingang Laboratory","award":["LGL-2611-02"],"award-info":[{"award-number":["LGL-2611-02"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nonsense mutations introduce premature termination codons (PTCs) that trigger mRNA degradation and underlie genetic diseases, including Alport syndrome (AS). Suppressor tRNAs (sup-tRNAs) are potential therapies for such disorders, as they can precisely readthrough PTCs and restore full-length protein synthesis. For AS caused by COL4A5 nonsense-mediated deficiency, we developed a TDN-sup-tRNA delivery strategy using tetrahedral DNA nanostructures (TDNs) characterized by excellent biocompatibility and renal targeting. In a Col4a5-R471X mouse model, TDN-sup-tRNA achieved high readthrough efficiency, restoring COL4A5 protein expression and reconstituting glomerular basement membrane integrity. Notably, proteinuria was reduced to 35% of baseline within 4 weeks. Compared with AAV2\/9-mediated delivery, this system exhibited enhanced renal targeting and superior therapeutic efficacy over a one-month treatment period, without detectable toxicity. Collectively, this strategy represents a safe and effective non-viral RNA therapeutic approach for precise correction of nonsense mutation\u2013associated renal diseases.<\/jats:p>","DOI":"10.1093\/narmme\/ugag029","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:35:11Z","timestamp":1781613311000},"source":"Crossref","is-referenced-by-count":0,"title":["Tetrahedral DNA nanostructure-delivered suppressor tRNA ameliorates nephropathy in\n                    <i>COL4A5<\/i>\n                    nonsense mutation-mediated Alport syndrome mice"],"prefix":"10.1093","volume":"3","author":[{"given":"Jingru","family":"Lv","sequence":"first","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Hong","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Shen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyuan","family":"Mi","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8383-3010","authenticated-orcid":false,"given":"Zhetao","family":"Zheng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangyan","family":"Kong","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wankai","family":"Gao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyang","family":"Dou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songlin","family":"Tian","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5509-6981","authenticated-orcid":false,"given":"Qing","family":"Xia","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"2026062504453903500_B1","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1056\/NEJMra022296","article-title":"Alport\u2019s syndrome, Goodpasture\u2019s syndrome, and type IV collagen","volume":"348","author":"Hudson","year":"2003","journal-title":"N Engl J Med"},{"key":"2026062504453903500_B2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrneph.2012.259","article-title":"Alport syndrome\u2013insights from basic and clinical research","volume":"9","author":"Kruegel","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2026062504453903500_B3","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/sj.ejhg.5201649","article-title":"Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease","volume":"14","author":"Khajavi","year":"2006","journal-title":"Eur J Hum Genet"},{"key":"2026062504453903500_B4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.tig.2020.11.002","article-title":"To NMD or not To NMD: nonsense-mediated mRNA decay in cancer and other genetic diseases","volume":"37","author":"Supek","year":"2021","journal-title":"Trends Genet"},{"key":"2026062504453903500_B5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molmed.2023.01.004","article-title":"Readthrough compounds for nonsense mutations: bridging the translational gap","volume":"29","author":"Spelier","year":"2023","journal-title":"Trends Mol Med"},{"key":"2026062504453903500_B6","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00439-020-02199-3","article-title":"The Human Gene Mutation Database (HGMD\u00ae): optimizing its use in a clinical diagnostic or research setting","volume":"139","author":"Stenson","year":"2020","journal-title":"Hum Genet"},{"key":"2026062504453903500_B7","doi-asserted-by":"publisher","first-page":"e1641","DOI":"10.1002\/wrna.1641","article-title":"Therapeutic promise of engineered nonsense suppressor tRNAs","volume":"12","author":"Porter","year":"2021","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"2026062504453903500_B8","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.3390\/ijms20133329","article-title":"Strategies against nonsense: oxadiazoles as translational readthrough-inducing drugs (TRIDs)","volume":"20","author":"Campofelice","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026062504453903500_B9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s10020-018-0024-7","article-title":"Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons","volume":"24","author":"Dabrowski","year":"2018","journal-title":"Mol Med"},{"key":"2026062504453903500_B10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41573-023-00829-9","article-title":"tRNA therapeutics for genetic diseases","volume":"23","author":"Coller","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026062504453903500_B11","doi-asserted-by":"publisher","first-page":"108919","DOI":"10.1016\/j.pharmthera.2025.108919","article-title":"Suppressor tRNAs as personalized therapy for nonsense mutation-associated pathologies","volume":"274","author":"Ignatova","year":"2025","journal-title":"Pharmacol Ther"},{"key":"2026062504453903500_B12","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1038\/s41467-021-24076-x","article-title":"Repurposing tRNAs for nonsense suppression","volume":"12","author":"Albers","year":"2021","journal-title":"Nat Commun"},{"key":"2026062504453903500_B13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41467-019-08329-4","article-title":"Engineered transfer RNAs for suppression of premature termination codons","volume":"10","author":"Lueck","year":"2019","journal-title":"Nat Commun"},{"key":"2026062504453903500_B14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-022-04533-3","article-title":"AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice","volume":"604","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"2026062504453903500_B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02982-5","article-title":"An engineered UGA suppressor tRNA gene for disease-agnostic AAV delivery","author":"Xu","year":"2026","journal-title":"Nat Biotechnol"},{"key":"2026062504453903500_B16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41586-025-09732-2","article-title":"Prime editing-installed suppressor tRNAs for disease-agnostic genome editing","volume":"648","author":"Pierce","year":"2025","journal-title":"Nature"},{"key":"2026062504453903500_B17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41586-023-06133-1","article-title":"Engineered tRNAs suppress nonsense mutations in cells and in vivo","volume":"618","author":"Albers","year":"2023","journal-title":"Nature"},{"key":"2026062504453903500_B18","doi-asserted-by":"publisher","first-page":"11185","DOI":"10.1038\/s41467-025-66176-y","article-title":"AAV-delivered engineered suppressor tRNA rescues visual function in mice with an inherited retinal disease","volume":"16","author":"Ren","year":"2025","journal-title":"Nat Commun"},{"key":"2026062504453903500_B19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40291-020-00467-6","article-title":"Improving molecular therapy in the kidney","volume":"24","author":"Rubin","year":"2020","journal-title":"Mol Diagn Ther"},{"key":"2026062504453903500_B20","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1089\/hum.2019.127","article-title":"Comparison of gene delivery to the kidney by adenovirus, adeno-associated virus, and lentiviral vectors after intravenous and direct kidney injections","volume":"30","author":"Rubin","year":"2019","journal-title":"Hum Gene Ther"},{"key":"2026062504453903500_B21","doi-asserted-by":"publisher","first-page":"101534","DOI":"10.1016\/j.mtbio.2025.101534","article-title":"Nanomaterials for targeted therapy of kidney diseases: strategies and advances","volume":"31","author":"Wang","year":"2025","journal-title":"Materials Today Bio"},{"key":"2026062504453903500_B22","doi-asserted-by":"publisher","first-page":"e2201731","DOI":"10.1002\/adma.202201731","article-title":"A lysosome-activated tetrahedral nanobox for encapsulated siRNA delivery","volume":"34","author":"Gao","year":"2022","journal-title":"Adv Mater"},{"key":"2026062504453903500_B23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nnano.2012.73","article-title":"Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery","volume":"7","author":"Lee","year":"2012","journal-title":"Nature Nanotech"},{"key":"2026062504453903500_B24","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1186\/s12967-024-05837-w","article-title":"DNA tetrahedron nanoparticles service as a help carrier and adjvant of mRNA vaccine","volume":"22","author":"Liu","year":"2024","journal-title":"J Transl Med"},{"key":"2026062504453903500_B25","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/s41467-023-37020-y","article-title":"Lantern-shaped flexible RNA origami for Smad4 mRNA delivery and growth suppression of colorectal cancer","volume":"14","author":"Hu","year":"2023","journal-title":"Nat Commun"},{"key":"2026062504453903500_B26","doi-asserted-by":"publisher","first-page":"D184","DOI":"10.1093\/nar\/gkv1309","article-title":"GtRNAdb 2.0: an expanded database of transfer RNA genes identified in complete and draft genomes","volume":"44","author":"Chan","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2026062504453903500_B27","doi-asserted-by":"publisher","first-page":"14112","DOI":"10.1093\/nar\/gkae1112","article-title":"Optimization of ACE-tRNAs function in translation for suppression of nonsense mutations","volume":"52","author":"Porter","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2026062504453903500_B28","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1038\/s41467-024-47258-9","article-title":"Translation velocity determines the efficacy of engineered suppressor tRNAs on pathogenic nonsense mutations","volume":"15","author":"Bharti","year":"2024","journal-title":"Nat Commun"},{"key":"2026062504453903500_B29","doi-asserted-by":"publisher","first-page":"e52611","DOI":"10.7554\/eLife.52611","article-title":"Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides","volume":"9","author":"Wangen","year":"2020","journal-title":"Elife"},{"key":"2026062504453903500_B30","doi-asserted-by":"publisher","first-page":"103891","DOI":"10.1016\/j.isci.2022.103891","article-title":"NanoLuc reporters identify COL4A5 nonsense mutations susceptible to drug-induced stop codon readthrough","volume":"25","author":"Omachi","year":"2022","journal-title":"iScience"},{"key":"2026062504453903500_B31","doi-asserted-by":"publisher","first-page":"e0330804","DOI":"10.1371\/journal.pone.0330804","article-title":"Anticodon-edited tRNA enables translational readthrough of COL4A5 premature termination codons","volume":"20","author":"Omachi","year":"2025","journal-title":"PLoS One"},{"key":"2026062504453903500_B32","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/j.1523-1755.2005.00204.x","article-title":"Detection of mutations in the COL4A5 gene by analyzing cDNA of skin fibroblasts","volume":"67","author":"Wang","year":"2005","journal-title":"Kidney Int"},{"key":"2026062504453903500_B33","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ki.1993.104","article-title":"Isolation and characterization of complement receptor type 1 from rat glomerular epithelial cells","volume":"43","author":"Quigg","year":"1993","journal-title":"Kidney Int"},{"key":"2026062504453903500_B34","first-page":"1192","article-title":"X-linked Alport syndrome: an SSCP-based mutation survey over all 51 exons of the COL4A5 gene","volume":"58","author":"Renieri","year":"1996","journal-title":"Am J Hum Genet"},{"key":"2026062504453903500_B35","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41551-018-0317-8","article-title":"DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury","volume":"2","author":"Jiang","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"2026062504453903500_B36","doi-asserted-by":"publisher","first-page":"683247","DOI":"10.3389\/fbioe.2021.683247","article-title":"Targeted drug delivery systems for kidney diseases","volume":"9","author":"Huang","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"2026062504453903500_B37","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/ndt\/gfac233","article-title":"Targeted nanotherapy for kidney diseases: a comprehensive review","volume":"38","author":"Sabiu","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026062504453903500_B38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.kint.2025.04.024","article-title":"The enzyme SMPDL3b in podocytes decouples proteinuria from chronic kidney disease progression in experimental Alport syndrome","volume":"108","author":"Mitrofanova","year":"2025","journal-title":"Kidney Int"},{"key":"2026062504453903500_B39","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1016\/j.ymthe.2025.07.046","article-title":"Intercepting the complement amplification loop through podocyte MC5R signaling ameliorates membranous nephropathy","volume":"33","author":"Liu","year":"2025","journal-title":"Mol Ther"},{"key":"2026062504453903500_B40","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1038\/s41467-020-16605-x","article-title":"Development of an exon skipping therapy for X-linked alport syndrome with truncating variants in COL4A5","volume":"11","author":"Yamamura","year":"2020","journal-title":"Nat Commun"},{"key":"2026062504453903500_B41","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3109\/10409238.2012.694846","article-title":"Suppression of premature termination codons as a therapeutic approach","volume":"47","author":"Keeling","year":"2012","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"2026062504453903500_B42","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1039\/D3CC01123B","article-title":"The role of size in biostability of DNA tetrahedra","volume":"59","author":"Vilcapoma","year":"2023","journal-title":"Chem Commun"},{"key":"2026062504453903500_B43","doi-asserted-by":"publisher","first-page":"129495","DOI":"10.1016\/j.ijbiomac.2024.129495","article-title":"Improving DNA nanostructure stability: a review of the biomedical applications and approaches","volume":"260","author":"Nasiri","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"2026062504453903500_B44","doi-asserted-by":"publisher","first-page":"12749","DOI":"10.1038\/s41598-018-31158-2","article-title":"Collaboration of tRNA modifications and elongation factor eEF1A in decoding and nonsense suppression","volume":"8","author":"Klassen","year":"2018","journal-title":"Sci Rep"},{"key":"2026062504453903500_B45","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41594-024-01450-z","article-title":"Ribosomal A-site interactions with near-cognate tRNAs drive stop codon readthrough","volume":"32","author":"\u010capkov\u00e1\u00a0Pavl\u00edkov\u00e1","year":"2025","journal-title":"Nat Struct Mol Biol"},{"key":"2026062504453903500_B46","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature14896","article-title":"Structural basis for stop codon recognition in eukaryotes","volume":"524","author":"Brown","year":"2015","journal-title":"Nature"},{"key":"2026062504453903500_B47","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/nar\/gkad007","article-title":"The tRNA identity landscape for aminoacylation and beyond","volume":"51","author":"Gieg\u00e9","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2026062504453903500_B48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026062504453903500_B49","doi-asserted-by":"publisher","first-page":"gkaf730","DOI":"10.1093\/nar\/gkaf730","article-title":"High-fidelity and differential nonsense suppression in live cells and a frontotemporal dementia allele with human transfer RNAs","volume":"53","author":"Beharry","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"2026062504453903500_B50","doi-asserted-by":"publisher","first-page":"gkaf675","DOI":"10.1093\/nar\/gkaf675","article-title":"ACE-tRNAs are a platform technology for suppressing nonsense mutations that cause cystic fibrosis","volume":"53","author":"Ko","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"2026062504453903500_B51","doi-asserted-by":"publisher","first-page":"gkaf532","DOI":"10.1093\/nar\/gkaf532","article-title":"An engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations","volume":"53","author":"Specht","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"2026062504453903500_B52","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s12951-021-01164-0","article-title":"Tetrahedral DNA nanostructures for effective treatment of cancer: advances and prospects","volume":"19","author":"Yan","year":"2021","journal-title":"J Nanobiotechnol"},{"key":"2026062504453903500_B53","first-page":"100217","article-title":"Chemically modified DNA nanostructures for drug delivery","volume":"3","author":"Wang","year":"2022","journal-title":"Innovation (Camb)"},{"key":"2026062504453903500_B54","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat Biotechnol"},{"key":"2026062504453903500_B55","doi-asserted-by":"publisher","first-page":"e03534","DOI":"10.1002\/advs.202503534","article-title":"Anticodon engineered transfer RNA (tRNA(SUAG)) inhibits Hepatitis B virus replication by promoting the degradation of core protein","volume":"12","author":"Yang","year":"2025","journal-title":"Adv Sci"}],"container-title":["NAR Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/narmolmed\/advance-article-pdf\/doi\/10.1093\/narmme\/ugag029\/68537588\/ugag029.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/narmolmed\/article-pdf\/3\/2\/ugag029\/68537588\/ugag029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/narmolmed\/article-pdf\/3\/2\/ugag029\/68537588\/ugag029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:45:50Z","timestamp":1782377150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/narmolmed\/article\/doi\/10.1093\/narmme\/ugag029\/8709292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/narmme\/ugag029","relation":{},"ISSN":["2976-856X"],"issn-type":[{"value":"2976-856X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,30]]},"article-number":"ugag029"}}